Ignite Creation Date:
2025-12-24 @ 11:15 PM
Ignite Modification Date:
2025-12-25 @ 8:52 PM
Study NCT ID:
NCT01232556
Status:
TERMINATED
Last Update Posted:
2019-01-08
First Post:
2010-10-27
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Sponsor:
Pfizer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-04-04
Start Date Type:
ACTUAL
Primary Completion Date:
2014-03-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-03-28
Completion Date Type:
ACTUAL
First Submit Date:
2010-10-27
First Submit QC Date:
None
Study First Post Date:
2010-11-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-07-17
Results First Submit QC Date:
None
Results First Post Date:
2018-08-21
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2014-06-02
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2018-12-19
Last Update Post Date:
2019-01-08
Last Update Post Date Type:
ACTUAL